Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Charlene Flash
Baylor College of Medicine, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
Gilead Sciences, Inc.
Payment for services (e.g., consulting fees, honoraria, paid authorship)
The investigator periodically serves as an advisor to a company, Gilead Sciences, Inc. The company manufactures Truvada, a drug used for HIV prevention. The investigator’s research examines expansion of HIV prevention efforts in primary care, including the use of Truvada. The RCOI committee determined that this SFI is related to the investigator’s institutional responsibilities and has the potential to directly and/or significantly affect the research. Truvada is the first agent approved by the FDA for use in HIV prevention. This study is about providing and informing patients on the use of the drug, and the company is the sole manufacturer of the drug. The committee further determined that this SFI is a FCOI because the SFI could reasonably be affected by the research, and because the Investigator is involved in the design, conduct, and reporting of the research.
Developing an Implementation Program to Optimize Uptake of HIV Pre-Exposure Prophylaxis among Black Women in Primary Care Settings
CDC recently issued guidelines supporting use of a highly effective biomedical intervention to prevent HIV transmission, oral pre-exposure prophylaxis (PrEP). Although Black women in the United States bear disproportionate burden of HIV, limited data exist on how patient and provider features may influence their use of PrEP. This proposal is innovative in its use of implementation science to map out a step-wise approach to increasing PrEP access in a marginalized under-studied population.
Filed on September 01, 2017.
Tell us what you know about Charlene Flash's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Charlene Flash filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Charlene Flash | Baylor College of Medicine | Conflict of Interest | Gilead Sciences, Inc. | $5,000 - $9,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.